1-(4-氟苯基)环戊烷腈 | 83706-50-7

• 物质功能分类: 有机原料 - 有机氟化合物 - 氟苯腈系列
• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 中文名称: 1-(4-氟苯基)环戊烷腈
• 中文别名: 1-(4-氟苯基)环戊烷甲腈
• 英文名称: 1-(4-fluorophenyl)cyclopentane-1-carbonitrile
• 英文别名: 1-(4-Fluorophenyl)cyclopentanecarbonitrile
• CAS: 83706-50-7
• 化学式: C₁₂H₁₂FN
• 分子量: 189.232
• InChiKey: MAGOCEYAQAZRNE-UHFFFAOYSA-N

物化性质

• 沸点：
  303.5±35.0 °C(Predicted)
• 密度：
  1.0913 (estimate)
• 稳定性/保质期：
  遵照规定使用和储存，则不会分解。

计算性质

• 辛醇/水分配系数(LogP)：
  3.1
• 重原子数：
  14
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.42
• 拓扑面积：
  23.8
• 氢给体数：
  0
• 氢受体数：
  2

安全信息

• 危险品标志：
  Xn
• 安全说明：
  S26,S36/37/39
• 危险类别码：
  R20/21/22,R36/37/38
• 海关编码：
  2926909090
• 危险品运输编号：
  UN 3276
• 储存条件：
  应存于阴凉干燥环境中。

SDS

Name:	1-(4-Fluorophenyl)Cyclopentanecarbonitrile 99% Material Safety Data Sheet
Synonym:	None Known
CAS:	83706-50-7

Section 1 - Chemical Product MSDS Name:1-(4-Fluorophenyl)Cyclopentanecarbonitrile 99% Material Safety Data Sheet
Synonym:None Known

---

Section 2 - COMPOSITION, INFORMATION ON INGREDIENTS

CAS#	Chemical Name	content	EINECS#
83706-50-7	1-(4-Fluorophenyl)Cyclopentanecarbonit	99	280-526-7

Hazard Symbols: XN
Risk Phrases: 20/21/22 36/37/38

---

Section 3 - HAZARDS IDENTIFICATION
EMERGENCY OVERVIEW
Harmful by inhalation, in contact with skin and if swallowed.
Irritating to eyes, respiratory system and skin.
Potential Health Effects
Eye:
Causes eye irritation. May cause chemical conjunctivitis.
Skin:
Causes skin irritation. May be metabolized to cyanide which in turn acts by inhibiting cytochrome oxidase impairing cellular respiration.
Ingestion:
May cause gastrointestinal irritation with nausea, vomiting and diarrhea. May cause cardiac disturbances. The toxicological properties of this substance have not been fully investigated. May cause central nervous system depression. Metabolism may release cyanide, which may result in headache, dizziness, weakness, collapse, unconsciousness and possible death. Ingestion may result in symptoms similar to cyanide poisoning which is characterized by asphyxiation.
Inhalation:
Causes respiratory tract irritation. May cause cardiac abnormalities. Can produce delayed pulmonary edema. May be metabolized to cyanide which in turns act by inhibiting cytochrome oxidase impairing cellular respiration. Inhalation at high concentrations may cause CNS depression and asphixiation.
Chronic:
May be metabolized to cyanide which in turn acts by inhibiting cytochrome oxidase impairing cellular respiration. Effects may be delayed. Chronic exposure to cyanide solutions may lead to the development of a "cyanide" rash, characterized by itching, and by macular, papular, and vesicular eruptions, and may be accompanied by secondary infections. Exposure to small amounts of cyanide compounds over long periods of time is reported to cause loss of appetite, headache, weakness, nausea, dizziness, and symptoms of irritation of the upper respiratory tract and eyes.

---

Section 4 - FIRST AID MEASURES
Eyes: Immediately flush eyes with plenty of water for at least 15 minutes, occasionally lifting the upper and lower eyelids. Get medical aid.
Skin:
Get medical aid. Immediately flush skin with plenty of water for at least 15 minutes while removing contaminated clothing and shoes.
Wash clothing before reuse.
Ingestion:
Never give anything by mouth to an unconscious person. Get medical aid. Do NOT induce vomiting. If conscious and alert, rinse mouth and drink 2-4 cupfuls of milk or water. Wash mouth out with water.
Inhalation:
Remove from exposure and move to fresh air immediately. If not breathing, give artificial respiration. If breathing is difficult, give oxygen. Get medical aid. Do NOT use mouth-to-mouth resuscitation.
Notes to Physician:
Treat symptomatically and supportively. May be partially metabolized to cyanide in the body.
Antidote: Always have a cyanide antidote kit on hand when working with cyanide compounds. Get medical advice to use.

---

Section 5 - FIRE FIGHTING MEASURES
General Information:
As in any fire, wear a self-contained breathing apparatus in pressure-demand, MSHA/NIOSH (approved or equivalent), and full protective gear. During a fire, irritating and highly toxic gases may be generated by thermal decomposition or combustion. Vapors may be heavier than air. They can spread along the ground and collect in low or confined areas. Runoff from fire control or dilution water may cause pollution.
Extinguishing Media:
Use water spray, dry chemical, carbon dioxide, or appropriate foam.

---

Section 6 - ACCIDENTAL RELEASE MEASURES
General Information: Use proper personal protective equipment as indicated in Section 8.
Spills/Leaks:
Absorb spill with inert material (e.g. vermiculite, sand or earth), then place in suitable container. Avoid runoff into storm sewers and ditches which lead to waterways. Clean up spills immediately, observing precautions in the Protective Equipment section. Provide ventilation.

---

Section 7 - HANDLING and STORAGE
Handling:
Avoid breathing dust, vapor, mist, or gas. Avoid contact with eyes, skin, and clothing. Keep container tightly closed. Avoid ingestion and inhalation. Use with adequate ventilation. Wash clothing before reuse.
Storage:
Store in a tightly closed container. Store in a cool, dry, well-ventilated area away from incompatible substances.

---

Section 8 - EXPOSURE CONTROLS, PERSONAL PROTECTION
Engineering Controls:
Facilities storing or utilizing this material should be equipped with an eyewash facility and a safety shower. Use adequate ventilation to keep airborne concentrations low.
Exposure Limits CAS# 83706-50-7: Personal Protective Equipment Eyes: Wear appropriate protective eyeglasses or chemical safety goggles as described by OSHA's eye and face protection regulations in 29 CFR 1910.133 or European Standard EN166.
Skin:
Wear appropriate protective gloves to prevent skin exposure.
Clothing:
Wear appropriate protective clothing to prevent skin exposure.
Respirators:
Follow the OSHA respirator regulations found in 29 CFR 1910.134 or European Standard EN 149. Use a NIOSH/MSHA or European Standard EN 149 approved respirator if exposure limits are exceeded or if irritation or other symptoms are experienced.

---

Section 9 - PHYSICAL AND CHEMICAL PROPERTIES

Physical State: Clear liquid
Color: slightly yellow
Odor: Not available.
pH: Not available.
Vapor Pressure: Not available.
Viscosity: Not available.
Boiling Point: Not available.
Freezing/Melting Point: Not available.
Autoignition Temperature: Not available.
Flash Point: Not available.
Explosion Limits, lower: Not available.
Explosion Limits, upper: Not available.
Decomposition Temperature:
Solubility in water:
Specific Gravity/Density:
Molecular Formula: C12H12FN
Molecular Weight: 189.0891

---

Section 10 - STABILITY AND REACTIVITY
Chemical Stability:
Stable at room temperature in closed containers under normal storage and handling conditions.
Conditions to Avoid:
Incompatible materials, excess heat.
Incompatibilities with Other Materials:
Oxidizing agents.
Hazardous Decomposition Products:
Carbon monoxide, oxides of nitrogen, carbon dioxide, hydrogen fluoride gas.
Hazardous Polymerization: Has not been reported

---

Section 11 - TOXICOLOGICAL INFORMATION
RTECS#:
CAS# 83706-50-7 unlisted.
LD50/LC50:
Not available.
Carcinogenicity:
1-(4-Fluorophenyl)Cyclopentanecarbonitrile - Not listed by ACGIH, IARC, or NTP.

---

Section 12 - ECOLOGICAL INFORMATION

---

Section 13 - DISPOSAL CONSIDERATIONS
Dispose of in a manner consistent with federal, state, and local regulations.

---

Section 14 - TRANSPORT INFORMATION

IATA
Shipping Name: Not regulated.
Hazard Class:
UN Number:
Packing Group:
IMO
Shipping Name: Not regulated.
Hazard Class:
UN Number:
Packing Group:
RID/ADR
Shipping Name: Not regulated.
Hazard Class:
UN Number:
Packing group:

---

Section 15 - REGULATORY INFORMATION

European/International Regulations
European Labeling in Accordance with EC Directives
Hazard Symbols: XN
Risk Phrases:
R 20/21/22 Harmful by inhalation, in contact with
skin and if swallowed.
R 36/37/38 Irritating to eyes, respiratory system
and skin.
Safety Phrases:
S 26 In case of contact with eyes, rinse immediately
with plenty of water and seek medical advice.
S 36/37/39 Wear suitable protective clothing, gloves
and eye/face protection.
WGK (Water Danger/Protection)
CAS# 83706-50-7: No information available.
Canada
None of the chemicals in this product are listed on the DSL/NDSL list.
CAS# 83706-50-7 is not listed on Canada's Ingredient Disclosure List.
US FEDERAL
TSCA
CAS# 83706-50-7 is not listed on the TSCA inventory.
It is for research and development use only.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

反应信息

• 作为反应物：
  描述：

  1-(4-氟苯基)环戊烷腈 在 硫酸 、 palladium 10% on activated carbon 、 二苯基膦叠氮化物 、 水 、 氢气 、 三乙酰氧基硼氢化钠 、 溶剂黄146 、 三乙胺 作用下， 以 乙醇 、 二氯甲烷 、 乙酸乙酯 、 甲苯 为溶剂， 反应 74.0h， 生成 N-[1-(4-fluorophenyl)cyclopentyl]-1-(2-phenylethyl)piperidine-4-carboxamide
  参考文献：
  名称：

  Synthesis and Pharmacological Evaluation of 1-Alkyl-N-[(1R)-1-(4-fluorophenyl)-2-methylpropyl]piperidine-4-carboxamide Derivatives as Novel Antihypertensive Agents

  摘要：

  我们合成并评估了一系列1-烷基-N-[(1R)-1-(4-氟苯基)-2-甲基丙基]哌啶-4-羧酰胺衍生物对T型钙通道的抑制活性。结构-活性关系研究表明，苄位异丙基取代基在发挥强效抑制活性中起着重要作用，并且苄位的绝对构型与作为新型T型钙通道阻滞剂首次上市的米贝地尔相反。N-[(1R)-1-(4-氟苯基)-2-甲基丙基]-1-[2-(3-甲氧基苯基)乙基]哌啶-4-羧酰胺（17f）的口服给药能降低自发性高血压大鼠的血压，而不会引起反射性心动过速，这是传统L型钙通道阻滞剂常见的不良反应。

  DOI：

  10.1248/cpb.59.1376
• 作为产物：
  描述：

  1,4-二溴丁烷 、 对氟苯乙腈 在 四丁基溴化铵 、 potassium hydroxide 作用下， 以 水 、 甲苯 为溶剂， 以94 %的产率得到1-(4-氟苯基)环戊烷腈
  参考文献：
  名称：

  钴催化的 Wagner-Meerwein 重排伴随亲核氢氟化

  摘要：

  已经开发出一种钴催化反应，该反应通过氢原子转移和自由基极性交叉步骤进行，在非酸性条件下形成苯鎓离子。该阳离子中间体可以被四氟硼酸根阴离子区域选择性氟化，得到 1,2-芳基迁移产物。对明显取代的苯鎓离子中间体的评估表明了良好反应性和高选择性的限制。

  DOI：

  10.1002/anie.202308048

文献信息

• [EN] INHIBITOR OF INDOLEAMINE-2,3-DIOXYGENASE (IDO)<br/>[FR] INHIBITEUR DE L'INDOLÉAMINE-2,3-DIOXYGÉNASE (IDO)
  申请人：INVENTISBIO INC

  公开号：WO2017139414A1

  公开（公告）日：2017-08-17

  The present disclosure provides compounds of Formula (I). The compounds described herein may be useful in treating a disease associated with IDO, for example, cancer or an infectious disease (e.g., viral or bacterial infectious diseases). Also, provided in the present disclosure are pharmaceutical compositions, kits, methods, and uses including or using a compound described herein.

  本公开提供了式（I）的化合物。本文描述的化合物可能在治疗与IDO相关的疾病方面有用，例如癌症或传染病（例如病毒或细菌感染性疾病）。本公开还提供了包括或使用本文描述的化合物的药物组合物、试剂盒、方法和用途。
• CHEMOSELECTIVE METHYLENE HYDROXYLATION IN AROMATIC MOLECULES
  申请人：The Board of Trustees of the University of Illinois

  公开号：US20200087331A1

  公开（公告）日：2020-03-19

  A chemoselective and reactive Mn(CF 3 -PDP) catalyst system that enables for the first time the strategic advantages of late-stage aliphatic C—H hydroxylation to be leveraged in aromatic compounds. This discovery will benefit small molecule therapeutics by enabling the rapid diversification of aromatic drugs and natural products and identification of their metabolites.

  一种化学选择性和反应性的Mn(CF3-PDP)催化体系首次实现了后期脂肪族C—H羟基化在芳香化合物中的战略优势。这一发现将有助于小分子药物的快速多样化和芳香类药物以及天然产物的代谢产物的鉴定。
• 酰胺化合物及其衍生物，制备方法、药物组合物和应用
  申请人：中国药科大学

  公开号：CN113061098B

  公开（公告）日：2022-08-30

  本发明公开了一类酰胺化合物及其衍生物，制备方法、药物组合物和应用。该类酰胺化合物结构如式(I)，该类酰胺化合物衍生物涉及所述酰胺化合物的立体异构体、互变异构体、代谢产物、代谢前体、前药、溶剂化物、溶剂化物的盐、结晶、药学上可接受的盐或它们的混合物。该类酰胺化合物及其衍生物对吲哚胺2,3‑双加氧酶1具有高效的抑制作用，可用于制备治疗吲哚胺2,3‑双加氧酶1介导的免疫抑制相关疾病的药物，所制备药物在分子水平即可发挥药效，应用广泛，并且该类化合物合成方法简便，易操作。
• Chemoselective methylene oxidation in aromatic molecules
  作者：Jinpeng Zhao、Takeshi Nanjo、Emilio C. de Lucca、M. Christina White

  DOI：10.1038/s41557-018-0175-8

  日期：2019.3

  labile aromatic functionalities remains a major unsolved problem. Such chemoselective reactivity is highly desirable for enabling late-stage oxidative derivatizations of pharmaceuticals and medicinally important natural products that often contain such functionality. Here, we report a simple manganese small-molecule catalyst Mn(CF3–PDP) system that achieves such chemoselectivity via an unexpected synergy

  尽管在过去十年中，位点选择性脂肪族C–H氧化的发展取得了重大进展，但是在存在更多易氧化的芳族官能团的情况下，能够氧化亚甲基C–H强键的能力仍然是一个主要未解决的问题。这种化学选择性反应性对于使通常包含这种功能性的药物和重要的天然药物能够进行后期的氧化衍生化是非常需要的。在这里，我们报告了一种简单的锰小分子催化剂Mn（CF 3-PDP）系统通过催化剂设计和酸添加剂的意外协同作用实现了这种化学选择性。在50种芳香族化合物中可进行制备型亚甲基远距离氧化，这些芳香族化合物具有可药用的卤素，氧，杂环和联芳基部分。在四种药物支架上均显示了晚期亚甲基氧化，包括乙炔雌二醇支架，在该支架上，其他可耐受芳香族基团的非定向CH氧化剂仅在活化的叔苄基位上进行氧化。证明了从高级中间体快速生成已知代谢物（吡拉格列汀）的方法。
• Process for preparing zeolites
  申请人：——

  公开号：US20020085976A1

  公开（公告）日：2002-07-04

  The present invention relates to a process for preparing zeolites using quaternary ammonium cations having the following formula as structure directing agents: 1 wherein: X is —H, methyl, —F, —Cl, —F and —Cl, or methoxy; R 1 and R 2 are each methyl or ethyl; R 1 and R 2 together are —(CH 2 ) x — where x is 2, 3, 4, or 5; or R 1 and R 2 together are methylated or dimethylated —(CH 2 ) y — where y is 3, 4, or 5; and R 3 , R 4 and R 5 are each methyl or ethyl, or one of R 3 , R 4 or R 5 is methyl and the other two together are —(CH 2 ) z — where z is 4, 5, 6 or 7;.

  本发明涉及一种使用季铵阳离子作为结构导向剂制备沸石的方法，所述季铵阳离子具有以下公式：1其中：X为—H、甲基、—F、—Cl、—F和—Cl、或甲氧基；R1和R2均为甲基或乙基；R1和R2在一起为—(CH2)x—，其中x为2、3、4或5；或者R1和R2在一起为甲基化或二甲基化的—(CH2)y—，其中y为3、4或5；而且R3、R4和R5均为甲基或乙基，或者R3、R4或R5之一为甲基，而另外两个在一起为—(CH2)z—，其中z为4、5、6或7。